Outcome of board meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd reported audited standalone financial results for FY26 with revenue from operations of Rs. 9,274 Lakhs, a massive jump from Rs. 64.02 Lakhs in FY25. Net profit after tax stood at Rs. 495.98 Lakhs compared to a loss of Rs. 108.56 Lakhs in the previous year, representing a significant turnaround. EPS for the year was Rs. 2.09 versus negative Rs. 0.99 in FY25. The company had to restate comparative figures due to first-time application of Ind AS 116 (Leases), recognizing cumulative depreciation of Rs. 3.41 Lakhs, finance costs of Rs. 1.66 Lakhs, and reversing rent expense of Rs. 4.32 Lakhs. Trade receivables increased dramatically to Rs. 7,077.60 Lakhs from Rs. 60.05 Lakhs, indicating a substantial change in business scale. The auditor issued an unmodified opinion with no going concern issues.
The company has turned profitable after a loss-making FY25, driven by a seemingly dramatic increase in revenue and business operations. However, the significant rise in trade receivables and the restatement of figures warrant scrutiny. The stock may see positive reaction to the profit turnaround.